默沙东(MRK.US)敦促股东拒绝Tutanota折价“迷你股权”收购要约

Core Viewpoint - Merck (MRK.US) has advised its shareholders to reject Tutanota's unsolicited "mini-tender" offer, indicating that accepting the offer may result in selling shares at a price lower than the current Merck stock price [1] Group 1 - Tutanota proposed to acquire up to 1 million shares of Merck common stock at a price of $65.00 per share, which is nearly 25% lower than Merck's closing price on November 7, the last trading day before the offer [1] - The proposed price is also approximately 32% lower than Merck's stock closing price on November 20 [1] - Merck stated that the offer involves shares below the 5% threshold of its outstanding shares, thus avoiding regulatory scrutiny [1] Group 2 - Merck does not endorse the offer and warns that, similar to Tutanota's previous offers, this one poses risks to individual investors who may not realize they are selling shares at a discount [1] - The company recommends shareholders reject the offer and informs those who have accepted it to withdraw before the December 15 deadline [1]